



COMMUNIVET™

Overview/description

Treating FIP with Bova GS-441524: Managing Patient Care and Treatment Expectations

You've made the diagnosis; you've started treatment with Bova GS-441524. What's next? As we learn more about feline infectious peritonitis (FIP) treatment, we continue to gather information about expected treatment responses and individual patient management.

In this edition of Kitty Academy, we will review FIP treatment choices and investigate the '*What ifs?*':

What if the patient does not respond?

What if the patient stops responding?

What if the patient relapses?

Speaker's bio and credentials



Kelly St. Denis, MSc, DVM, DABVP (feline practice)

Dr. St. Denis is board-certified with the American Board of Veterinary Practitioners in the specialty of feline practice. In her early career, she trained in molecular biology and immunology, working in the field of cancer research. In 1999, she graduated from the Ontario Veterinary College, and in 2007, she opened a feline specialty hospital, completing her ABVP certification in 2013. Dr. St. Denis is co-editor of the Journal of Feline Medicine and Surgery and JFMS Open Reports and medical co-editor of the AAFP Feline Practitioner Magazine. Currently, she works in clinical practice 2 days a week, is a consultant on the Veterinary Information Network, and lectures internationally on all things feline.



COMMUNIVET™

Questionnaire

1. **Which of the following statements is true:**
 - ☐ GS-441524 is a protease inhibitor used to treat feline infectious peritonitis
 - ☐ GS-441524 is only available in Canada through so-called 'black market' sources
 - ☐ GS-441524 should only be used as a second treatment option when patients fail to respond to molnupiravir
 - ☐ GS-441524 is a nucleoside analogue used to treat feline infectious peritonitis
2. **When determining treatment doses for Bova GS-441524, the following should be taken into consideration:**
 - ☐ The degree of severity of total bilirubinemia at diagnosis
 - ☐ Patient body weight as determined weekly throughout treatment
 - ☐ Presence of anemia at diagnosis
 - ☐ Presence of pyrexia, monitored daily during treatment
3. **Based on current published, peer-reviewed studies, >85% of FIP patients respond positively to Bova GS-441524. A failure to respond during the first week of treatment may indicate:**
 - ☐ The individual patient is not responding as expected to standard dosing recommendations
 - ☐ The medication was given on a full stomach, thus reducing absorption
 - ☐ The chosen dosing strategy was insufficient for the clinical presentation of FIP (effusive, non-effusive, ocular, or neurological)
 - ☐ All of the above
4. **If a relapse occurs after completion of treatment, the following course of action is recommended:**
 - ☐ Ensure that the current clinical signs are in fact a relapse of FIP, ruling out other differential diagnoses
 - ☐ Restart GS-441524 at the same dose as previously used and add a protease inhibitor such as GC-376
 - ☐ Restart GS-441524 at a higher dosage and add EIDD-1931
 - ☐ Recommend the client procure a 'black market' drug source for a second round of treatment



COMMUNIVET™

- 5. In addition to treatment with Bova GS-441524, if indicated, the patient should also receive supportive care, including:**
- Analgesia for pain from inflammation, distension from masses and/or effusions, uveitis, neuropathic pain
 - Appetite stimulants, anti-nausea drugs, and nutritional support (e.g., feeding tube)
 - Hydration support (e.g., feeding tube, intravenous fluids)
 - All of the above



COMMUNIVET™

PERSONAL INFORMATION:

First name:

Last name:

Type:

(Veterinarian, Technician)

Licence number:

Province where you practise:

Email:



COMMUNIVET™

CERTIFICATE OF COMPLETION

Educational webcast

**Treating FIP with Bova GS-441524:
Managing Patient Care and Treatment Expectations**

Presented by

Kelly St. Denis, MSc, DVM, DABVP (feline practice)

This document confirms that

Dr. Lorem Ipsum

has viewed the above-mentioned webcast and has answered and submitted the questionnaire meant to evaluate the understanding of the content.

Date:

Province of licensure:

Licence number:

CE credit (s) earned: 0.5